Infectious aneurysm

Infectious aneurysm

Infectious aneurysm (also known as mycotic aneurysm or microbial arteritis) is an aneurysm arising from bacterial infection of the arterial wall. It can be a common complicationof the hematogenous spread of bacterial infection.

William Osler first used the term “mycotic aneurysm” in 1885to describe a mushroom-shaped aneurysm in a patient with subacute bacterial endocarditis 1). rather than the current usage which infers a fungal etiology. Currently accepted terminology favors infectious aneurysm (or bacterial aneurysm). Infectious aneurysms can, however, also occur with fungal infections 2).

However, mycotic aneurysm is still used for all extracardiac or intracardiac aneurysms caused by infections, except for syphilitic aortitis.

The term “infected aneurysm,” proposed by Jarrett and associates is more appropriate, since few infections involve fungi.

According to some authors, a more accurate term might have been endovascular infection or infective vasculitis, because mycotic aneurysms are not due to a fungal organism.


1. comprise ≈ 4% of intracranial aneurysms.

2. Intracranial mycotic aneurysms (ICMAs) complicate about 2% to 3% of infective endocarditis (IE) cases, although as many as 15% to 29% of patients with IE have neurologic symptoms.

3. most common location: distal middle cerebral artery branches (75–80%)

4. at least 20% have or develop multiple intracranial aneurysms

5. increased frequency in immunocompromised patients (e.g. AIDS) and drug users

6. most probably start in the adventitia (outer layer) and spread inward

Left ventricular assist device-associated subarachnoid hemorrhage may be caused by infectious intracranial aneurysms when acute bloodstream infections are present 3).


streptococcus– 44% – S. viridans (classic cause of SBE)

staphylococcus– 18% S. aureus (cause of acute bacterial endocarditis)

miscellaneous – 6% (pseudomonasenterococcus, corynebacteria…)

multiple 5%

no growth 12%

no info 14%

total 99% 4).


Blood cultures and LP may identify the infectious organism. Patients with suspected infectious aneurysm(s) should undergo echocardiography to look for signs of endocarditis.


For the clinician, early diagnosis is the cornerstone of effective treatment. Without medical or surgical management, catastrophic hemorrhage or uncontrolled sepsis may occur. However, symptomatology is frequently nonspecific during the early stages, so a high index of suspicion is required to make the diagnosis.

These aneurysms usually have fusiform morphology and are usually very friable, therefore surgical treatment is difficult and/or risky. Most cases are treated acutely with antibiotics which are continued 4–6 weeks. Serial angiography (at 7–10 days and 1.5, 3, 6 and 12 months, even if aneurysms seem to be getting smaller, they may subsequently increase 5) and new ones may form) helps document the effectiveness of medical therapy (serial MRA may be a viable alternative in some cases). Aneurysms may continue to shrink following completion of antibiotic therapy 6). Delayed clipping may be more feasible; indications include:

1. patients with SAH.

2. increasing size of an aneurysm while on antibiotics (controversial, some say not mandatory) 7).

3. failure of the aneurysm to reduce in size after 4–6 weeks of antibiotics 8).

Patients with subacute bacterial endocarditis requiring valve replacement should have bioprosthetic (i.e. tissue) valves instead of mechanical valves to eliminate the need for risky anticoagulation.

Case reports

Lee et al. reported three left ventricular assist device recipients who presented with septicemia and developed subarachnoid hemorrhage. Case 1, a 37-year-old male with non-ischemic cardiomyopathy with HeartMate II, presented with confusion and found to have Serratia bloodstream infection and left frontal lobe subarachnoid hemorrhage. A cerebral angiography showed a right M3/M4 branch infectious intracranial aneurysm. He was treated with coil embolization and underwent device exchange. Case 2, a 41-year-old male with non-ischemic cardiomyopathy with HeartMate II presented with confusion and found to have methicillin-resistant staphylococcus aureus bloodstream infection and bilateral frontal convexity subarachnoid hemorrhage. Cerebral angiogram showed left M3 and left A3 infectious intracranial aneurysms, which were treated with antibiotics alone. Case 3, a 58-year-old female with ischemic cardiomyopathy with HeartMate II presented with fever, found to have candida albicans bloodstream infection and a parieto-occipital enhancing lesion concerning for cerebral abscess. Repeat computed tomography brain a week later showed a new right frontal subarachnoid hemorrhage. Cerebral angiogram showed a M4/M5 junction infectious intracranial aneurysm; patient was not a surgical candidate and was transitioned to hospice. This case series emphasizes that left ventricular assist device-associated subarachnoid hemorrhage may be caused by infectious intracranial aneurysms when acute bloodstream infections are present 9).

Khan et al.reported two cases of a ruptured mycotic aneurysm with intracerebral hematoma and impending brain herniation. Both patients had signs of high intracranial pressure and required urgent surgical evacuation of a clot. One patient survived while the other patient expired soon after surgery.

Mycotic aneurysm of middle cerebral artery (MCA) in IE with intracranial hemorrhage is rare and urgent surgical decompression, and aneurysmal clipping can be lifesaving 10).



Bohmfalk GL, Story JL, Wissinger JP, et al. Bacterial Intracranial Aneurysm. J Neurosurg. 1978; 48:369–382

Horten BC, Abbott GF, Porro RS. Fungal Aneurysms of Intracranial Vessels. Arch Neurol. 1976; 33:577– 579

Lee T, Buletko AB, Matthew J, Cho SM. Bloodstream infection is associated with subarachnoid hemorrhage and infectious intracranial aneurysm in left ventricular assist device. Perfusion. 2019 Jul 24:267659119858853. doi: 10.1177/0267659119858853. [Epub ahead of print] PubMed PMID: 31339450.

Schmidek HH, Sweet WH. Operative Neurosurgical Techniques. New York 1982

Pootrakul A, Carter LP. Bacterial Intracranial Aneurysm: Importance of Sequential Angiography. Surg Neurol. 1982; 17:429–431
6) , 7)

Morawetz RB, Karp RB. Evolution and Resolution of Intracranial Bacterial (Mycotic) Aneurysms. Neurosurgery. 1984; 15:43–49

Bingham WF. Treatment of Mycotic Intracranial Aneurysms. J Neurosurg. 1977; 46:428–437

Lee T, Buletko AB, Matthew J, Cho SM. Bloodstream infection is associated with subarachnoid hemorrhage and infectious intracranial aneurysm in left ventricular assist device. Perfusion. 2019 Jul 24:267659119858853. doi: 10.1177/0267659119858853. [Epub ahead of print] PubMed PMID: 31339450.

Khan A, Waqas M, Nizamani WM, Bari ME. Ruptured mycotic aneurysms: Report and outcomes of two surgically managed patients. Surg Neurol Int. 2017 Jul 11;8:144. doi: 10.4103/sni.sni_78_17. eCollection 2017. PubMed PMID: 28781921; PubMed Central PMCID: PMC5523478.

Malignant middle cerebral artery infarction outcome

Malignant middle cerebral artery infarction outcome

Malignant middle cerebral artery infarction is associated with high mortality and morbidity.

The mortality rate of patients with brain edema after malignant middle cerebral artery (MCA) infarction approaches 80 % without surgical intervention 1).

Over the past 10 years in Francedecompressive craniectomy (DC) has been increasingly performed for malignant middle cerebral artery infarction (MCI) regardless of age. However, in-hospital mortality remains considerable, as about one-quarter of patients died within the first weeks. For those who survive beyond 6 months, the risk of death significantly decreases. Early mortality is especially high for comatose patients above 60 years operated in inexperienced centers. Most of those who remain in good functional status tend to undergo a cranioplasty within the year following DC 2).

Three separate studies investigated the effectiveness of decompressive craniectomy after malignant MCA infarction in controlled trials with patients less than 61 years of age 3) 4) 5). These were demonstrated that hemicraniectomy reduced the mortality rate by 49% at one year after stroke when compared with conventional medical treatments. However, the question of how applicable the results are to patients older than 60 years of age still remains unanswered.

When neurosurgeons recommend decompressive surgery for patients with malignant infarcts, patients’ relatives often refuse the operation because of the patients’ age, past medical history or comorbidity. Such a situation occurs more frequently when the patient is older than 70 years of age 6).



Huttner HB, Schwab S. Malignant middle cerebral artery infarction: clinical characteristics, treatment strategies, and future perspectives. Lancet Neurol 2009; 8:949–958.

Champeaux C, Weller J. Long-Term Survival After Decompressive Craniectomy for Malignant Brain Infarction: A 10-Year Nationwide Study. Neurocrit Care. 2019 Jul 9. doi: 10.1007/s12028-019-00774-9. [Epub ahead of print] PubMed PMID: 31290068.

Hofmeijer J, Kappelle LJ, Algra A, Amelink GJ, van Gijn J, van der Worp HB, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol. 2009 Apr;8(4):326–333.

Jüttler E, Schwab S, Schmiedek P, Unterberg A, Hennerici M, Woitzik J, et al. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke. 2007 Sep;38(9):2518–2525.

Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard JP, et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial) Stroke. 2007 Sep;38(9):2506–2517.

Yu JW, Choi JH, Kim DH, Cha JK, Huh JT. Outcome following decompressive craniectomy for malignant middle cerebral artery infarction in patients older than 70 years old. J Cerebrovasc Endovasc Neurosurg. 2012 Jun;14(2):65-74. doi: 10.7461/jcen.2012.14.2.65. Epub 2012 Jun 30. PubMed PMID: 23210030; PubMed Central PMCID: PMC3471258.
WhatsApp WhatsApp us
%d bloggers like this: